169 related articles for article (PubMed ID: 17099725)
1. Ink4c is dispensable for tumor suppression in Myc-induced B-cell lymphomagenesis.
Nilsson LM; Keller UB; Yang C; Nilsson JA; Cleveland JL; Roussel MF
Oncogene; 2007 May; 26(20):2833-9. PubMed ID: 17099725
[TBL] [Abstract][Full Text] [Related]
2. Nfkb 1 is dispensable for Myc-induced lymphomagenesis.
Keller U; Nilsson JA; Maclean KH; Old JB; Cleveland JL
Oncogene; 2005 Sep; 24(41):6231-40. PubMed ID: 15940251
[TBL] [Abstract][Full Text] [Related]
3. Targeting ornithine decarboxylase in Myc-induced lymphomagenesis prevents tumor formation.
Nilsson JA; Keller UB; Baudino TA; Yang C; Norton S; Old JA; Nilsson LM; Neale G; Kramer DL; Porter CW; Cleveland JL
Cancer Cell; 2005 May; 7(5):433-44. PubMed ID: 15894264
[TBL] [Abstract][Full Text] [Related]
4. AID and RAG1 do not contribute to lymphomagenesis in Emu c-myc transgenic mice.
Nepal RM; Zaheen A; Basit W; Li L; Berger SA; Martin A
Oncogene; 2008 Aug; 27(34):4752-6. PubMed ID: 18408759
[TBL] [Abstract][Full Text] [Related]
5. MIF loss impairs Myc-induced lymphomagenesis.
Talos F; Mena P; Fingerle-Rowson G; Moll U; Petrenko O
Cell Death Differ; 2005 Oct; 12(10):1319-28. PubMed ID: 15947793
[TBL] [Abstract][Full Text] [Related]
6. Id2 is dispensable for myc-induced lymphomagenesis.
Nilsson JA; Nilsson LM; Keller U; Yokota Y; Boyd K; Cleveland JL
Cancer Res; 2004 Oct; 64(20):7296-301. PubMed ID: 15492249
[TBL] [Abstract][Full Text] [Related]
7. A non-transgenic mouse model for B-cell lymphoma: in vivo infection of p53-null bone marrow progenitors by a Myc retrovirus is sufficient for tumorigenesis.
Yu D; Thomas-Tikhonenko A
Oncogene; 2002 Mar; 21(12):1922-7. PubMed ID: 11896625
[TBL] [Abstract][Full Text] [Related]
8. Transgenic N-myc mouse model for indolent B cell lymphoma: tumor characterization and analysis of genetic alterations in spontaneous and retrovirally accelerated tumors.
Sheppard RD; Samant SA; Rosenberg M; Silver LM; Cole MD
Oncogene; 1998 Oct; 17(16):2073-85. PubMed ID: 9798678
[TBL] [Abstract][Full Text] [Related]
9. Insertion of c-Myc into Igh induces B-cell and plasma-cell neoplasms in mice.
Park SS; Kim JS; Tessarollo L; Owens JD; Peng L; Han SS; Tae Chung S; Torrey TA; Cheung WC; Polakiewicz RD; McNeil N; Ried T; Mushinski JF; Morse HC; Janz S
Cancer Res; 2005 Feb; 65(4):1306-15. PubMed ID: 15735016
[TBL] [Abstract][Full Text] [Related]
10. Loss of Fas/Apo-1 receptor accelerates lymphomagenesis in E mu L-MYC transgenic mice but not in animals infected with MoMuLV.
Zörnig M; Grzeschiczek A; Kowalski MB; Hartmann KU; Möröy T
Oncogene; 1995 Jun; 10(12):2397-401. PubMed ID: 7784089
[TBL] [Abstract][Full Text] [Related]
11. Synergistic effect of oncogenic RET and loss of p18 on medullary thyroid carcinoma development.
van Veelen W; van Gasteren CJ; Acton DS; Franklin DS; Berger R; Lips CJ; Höppener JW
Cancer Res; 2008 Mar; 68(5):1329-37. PubMed ID: 18316595
[TBL] [Abstract][Full Text] [Related]
12. The functional basis of c-myc and bcl-2 complementation during multistep lymphomagenesis in vivo.
Marin MC; Hsu B; Stephens LC; Brisbay S; McDonnell TJ
Exp Cell Res; 1995 Apr; 217(2):240-7. PubMed ID: 7698223
[TBL] [Abstract][Full Text] [Related]
13. Runx2 and MYC collaborate in lymphoma development by suppressing apoptotic and growth arrest pathways in vivo.
Blyth K; Vaillant F; Hanlon L; Mackay N; Bell M; Jenkins A; Neil JC; Cameron ER
Cancer Res; 2006 Feb; 66(4):2195-201. PubMed ID: 16489021
[TBL] [Abstract][Full Text] [Related]
14. A murine model for B-cell lymphomagenesis in immunocompromised hosts: c-myc-rearranged B-cell lines with a premalignant phenotype.
Felsher DW; Denis KA; Weiss D; Ando DT; Braun J
Cancer Res; 1990 Nov; 50(21):7042-9. PubMed ID: 2208171
[TBL] [Abstract][Full Text] [Related]
15. Loss of one allele of ARF rescues Mdm2 haploinsufficiency effects on apoptosis and lymphoma development.
Eischen CM; Alt JR; Wang P
Oncogene; 2004 Nov; 23(55):8931-40. PubMed ID: 15467748
[TBL] [Abstract][Full Text] [Related]
16. Myc targets Cks1 to provoke the suppression of p27Kip1, proliferation and lymphomagenesis.
Keller UB; Old JB; Dorsey FC; Nilsson JA; Nilsson L; MacLean KH; Chung L; Yang C; Spruck C; Boyd K; Reed SI; Cleveland JL
EMBO J; 2007 May; 26(10):2562-74. PubMed ID: 17464290
[TBL] [Abstract][Full Text] [Related]
17. Disruption of the ARF-Mdm2-p53 tumor suppressor pathway in Myc-induced lymphomagenesis.
Eischen CM; Weber JD; Roussel MF; Sherr CJ; Cleveland JL
Genes Dev; 1999 Oct; 13(20):2658-69. PubMed ID: 10541552
[TBL] [Abstract][Full Text] [Related]
18. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
[TBL] [Abstract][Full Text] [Related]
19. The translation factor eIF-4E promotes tumor formation and cooperates with c-Myc in lymphomagenesis.
Ruggero D; Montanaro L; Ma L; Xu W; Londei P; Cordon-Cardo C; Pandolfi PP
Nat Med; 2004 May; 10(5):484-6. PubMed ID: 15098029
[TBL] [Abstract][Full Text] [Related]
20. Chemoprevention of B-cell lymphomas by inhibition of the Myc target spermidine synthase.
Forshell TP; Rimpi S; Nilsson JA
Cancer Prev Res (Phila); 2010 Feb; 3(2):140-7. PubMed ID: 20103729
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
